Rules-Based Medicine’s Rat Kidney MAP | GenomeWeb
Rules-Based Medicine announced this week that it has commercialized a new biomarker panel to aid pharmaceutical and biotech companies evaluate renal toxicity in rats for pre-clinical drug trials.
RBM's Rat Kidney MAP (multi-analyte profile) “measures key biomarkers found in urine that can provide additional information about drug-induced damage to kidney cells,” the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.